Oct 31 2009
Pfizer today announced that it has received the requisite consents to amend certain provisions of the indenture governing the following outstanding debt securities (the Securities) of Wyeth, its wholly owned subsidiary:
D.F. King, the Tabulation Agent, has advised that as of the expiration of the consent solicitation at 5:00 p.m., New York City time, on October 29, 2009, Pfizer had received the requisite consents in respect of at least a majority in aggregate principal amount of Securities outstanding as of the record date, 5:00 p.m. New York City Time, October 14, 2009. As a result, Pfizer and Wyeth will enter into a supplemental indenture to amend the indenture governing the Securities. In addition, Pfizer will (i) issue an unconditional and irrevocable guarantee of the prompt payment, when due, of any amounts owed in respect of the Securities and (ii) make a payment to each holder who validly delivered its consent prior to the expiration of the solicitation and did not revoke such consent of $1.50 for each $1,000 principal amount of Securities to which such consent relates.
The detailed terms and conditions of the consent solicitation are set forth in a Consent Solicitation/Prospectus Supplement dated October 16, 2009, which has been filed with the Securities and Exchange Commission.
Barclays Capital acted as Solicitation Agent for the consent solicitation, and D.F. King acted as the Information Agent and Tabulation Agent.